|
VANCOUVER, Jan. 19 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ:QLTI;
TSX:QLT) today reported that its alliance partner, Novartis, announced global
Visudyne(R) (verteporfin) sales of approximately US$108 million for the
quarter and US$484 million for the year ended December 31, 2005. Visudyne
sales for the fourth quarter declined by 13% over the same quarter in 2004 and
the full year represented an increase of 8% over annual sales in 2004.
QLT will release its full financial results on Wednesday, February 22,
2006, at 7:30 a.m. ET.
QLT is a global biopharmaceutical company specializing in developing
treatments for eye diseases as well as dermatological and urological
conditions. We have combined our expertise in the discovery, development and
commercialization of innovative drug therapies with our two unique technology
platforms, photodynamic therapy and Atrigel(R), to create products such as
Visudyne(R) and Eligard(R). For more information, visit our web site at
http://www.qltinc.com.
QLT Inc. will hold an investor conference call to discuss year-end
results and 2006 guidance on Wednesday, February 22nd at 8:30 a.m. ET
(5:30 a.m. PT). The call will be broadcast live via the Internet at
http://www.qltinc.com. To participate on the call, please dial 1-800-525-6384 (North
America) or 780-409-1668 (International) before 8:30 a.m. ET. A replay of the
call will be available via the Internet and also via telephone at
1-800-695-1018 (North America) or 402-220-1753 (International), access code
9614255.
Atrigel is a registered trademark of QLT USA, Inc.
Visudyne is a registered trademark of Novartis AG.
Eligard is a registered trademark of Sanofi-aventis.
QLT Inc. is listed on The Nasdaq Stock Market under the trading symbol
"QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."
A full explanation of how QLT determines and recognizes revenue resulting
from Visudyne sales is contained in the financial statements contained in the
periodic reports on Forms 10-Q and 10-K, under the heading "Significant
Accounting Policies - Revenue Recognition." Visudyne sales are product sales
by Novartis under its alliance with QLT.
The Visudyne(R) sales figures in this press release are preliminary and
unaudited and are not a complete disclosure of our quarterly or annual
financial results. Certain statements in this press release constitute
"forward-looking statements" of QLT within the meaning of the Private
Securities Litigation Reform Act of 1995, which involve known and unknown
risks, uncertainties and other factors that may cause our actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. These statements are only predictions
and actual events or results may differ materially. Factors that could cause
such actual events or results expressed or implied by such forward-looking
statements to differ materially from any future results expressed or implied
by such statements are described in detail in QLTs Annual Information Form on
Form 10-K, quarterly reports on Form 10-Q and other filings with the U.S.
Securities and Exchange Commission and Canadian securities regulatory
authorities. Forward-looking statements are based on our current expectations
and QLT does not assume any obligation to update such information to reflect
later events or developments, except as may be required by law.
|
|
